Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
NCT07051707
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The dNerva Lung Denervation System is one-time treatment intended to improve breathing in Chronic Obstructive Pulmonary Disease (COPD) patients on standard medical care. The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System in the treatment of COPD.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- COPD
- Chronic Obstructive Pulmonary Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Nuvaira, Inc.
- Last updated on ClinicalTrials.gov
- April 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama-Birmingham Hospital - UAB Lung Health Center · Birmingham, AL
Florida · 1
- Mayo Clinic Jacksonville · Jacksonville, FL
Michigan · 1
- Henry Ford Hospital - Lung and Pulmonary Care · Detroit, MI
Ohio · 1
- Ohio State University Medical Center - Ohio State Lung Center · Columbus, OH
Pennsylvania · 2
- Penn Highlands - Lung Innovations/Clinical Research Associates · DuBois, PA
- Temple University - Temple Lung Center · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.